Expert consensus on the management of peripheral neuropathy in patients with lymphoma on brentuximab vedotin
Year: 2026
Type: article
Abstract: PURPOSE: Brentuximab vedotin (BV) represents a therapeutic advancement in the treatment of CD30-positive lymphomas, yet its clinical utility is often limited by BV-induced peripheral neuropathy (PN). Currently, evidence-based, BV-specific guidelines for the assessment and management of PN are scarce, resulting in variability in clinical practice. This study aimed to establish international expert consensus on the optimal assessment, monitoring and management strategies for BV-induced PN in patients with lymphoma. METHODS: A modified Delphi panel was conducted, engaging a total of 13 experts from eight different countries and representing haematology, neurology, dermatology, nursing and allied health disciplines. Panellists participated in three rounds of structured surveys, with statements developed based on a targeted literature review and guidance from an expert steering committee. Consensus was defined as ≥ 70% agreement/disagreement. Consensus was achieved on 60/87 (69%) statements across domains including risk factor assessment, symptom monitoring, pharmaceutical and non-pharmaceutical management. RESULTS: Key recommendations include routine risk profiling before BV initiation, use of validated assessment tools at baseline and throughout therapy, multidisciplinary collaboration, and early intervention for worsening PN. Areas of uncertainty and variability in PN management remain, particularly regarding management of intermediate-grade PN and optimal non-pharmacological strategies. CONCLUSION: These international consensus recommendations provide practical guidance for improving clinical management of BV-induced PN and highlight the importance of early identification, personalised care and multidisciplinary collaboration. Further research is needed to address persistent gaps and inform future clinical guidelines.
Source: Supportive Care in Cancer
Authors: Roser Velasco, José A. Sanches, Andreas A. Argyriou, Guido Cavaletti, Eva Domingo-Domenech, Alexander Fosså, Jaime Gállego Pérez-Larraya, Antonia Miranda Ruiz, Alex Molassiotis, André Neder Ramires Abdo, Pablo L. Ortiz-Romero, Susanna B. Park, Julia Scarisbrick, Lauren Urwin, Mian Wang, H. Miles Prince
Institutions: Universitat Autònoma de Barcelona, Bellvitge University Hospital, Biomedical Research Networking Center on Neurodegenerative Diseases, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Universidade de São Paulo, Agios Andreas Hospital, University of Milano-Bicocca, Duran i Reynals Hospital, Oslo University Hospital, Navarre Institute of Health Research, Clinica Universidad de Navarra, Hospital Costa del Sol, Aston University, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre, The University of Sydney, University of Birmingham, Guy's and St Thomas' NHS Foundation Trust, Hong Kong Polytechnic University, The University of Melbourne, Epworth Hospital, Peter MacCallum Cancer Centre
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,690
Funder: Takeda Pharmaceuticals U.S.A.
OpenAlex ID: W7222844006